ArticleFrontiers in public health2025
Analysis of the trends and predictions of tuberculosis burden in China from 1990 to 2021 based on the GBD database.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-Term Trends and Determinants of Tuberculosis Burden in China, 1990-2023: Insights from the Global Burden of Disease Study 2023.Pathogens (Basel, Switzerland) · 2026Article
- Tuberculosis incidence and mortality trends in mainland China, 2004-2024: control program and elimination progress.Tropical medicine and health · 2026Article
- Tuberculosis infection following administration of immune checkpoint inhibitors: a real world observational study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) is a major public health concern in China, exhibiting unique epidemiological traits and changing patterns. This study aims to assess the burden of TB in China from 1990 to 2021 and forecast the future. Methods: Data on TB burden indicators in China from 1990 to 2021 were collected from the Global Burden of Disease (GBD) database. The Joinpoint Regression (JPR) model was employed to assess trends in disease burden, with calculations of the annual percentage change (APC) and average annual percentage change (AAPC). The Auto-Regressive Integrated Moving Average (ARIMA) model and the Bayesian Age-Period-Cohort (BAPC) model were utilized to forecast trends in the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) over the next 15 years. Results: From 1990 to 2021, the incidence, mortality, and disability-adjusted life years (DALYs) of TB in China showed a declining trend, decreasing by 47.17, 78.14, and 81.25%, respectively, while the absolute number of TB cases increased by 32.96%. In 2021, the ASIR, age-standardized prevalence rate (ASPR), ASMR, and age-standardized DALY rate (ASDR) of TB in China were 36.28 per 100,000 (95% CI: 32.63-40.47), 30,557.45 per 100,000 (95% CI: 27,692.69-33,531.31), 1.91 per 100,000 (95% CI: 1.51-2.51), and 76.22 per 100,000 (95% CI: 62.59-94.45), respectively, reflecting reductions of 66.60, 2.83, 90.72, and 89.53% from 1990 levels. The burden of TB exhibited disparities across gender and age groups, with older males experiencing a higher burden than older females, and children under 5 years old demonstrating the highest incidence rate among all age groups. The JPR regression model indicated a significant decline in ASIR (AAPC = -3.49; 95% CI: -3.49 to -3.37; Conclusion: From 1990 to 2021, TB incidence, mortality, and DALYs in China demonstrated an overall downward trend, with similar declines observed in both male and female populations. Projections indicate that ASIR and ASMR will continue to decline from 2022 to 2036. These findings provide valuable insights for the development of public health strategies aimed at reducing the TB burden in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.